TRAEs | Sitravatinib and nivolumab-related | Sitravatinib-related | Nivolumab-related | |||
Grade 1–2 n (%) | Grade 3–4 | Grade 1–2 | Grade 3 | Grade 1–2 | Grade 3 | |
N (%) | N (%) | N (%) | N (%) | N (%) | ||
Total number of events | 11 (100) | 39 (100) | 9 (100) | |||
Total number of events by grade | 9 (81) | 2 (19) | 38 (97) | 1 (3) | 9 (100) | 0 |
Fatigue | 3 (27) | – | 3 (8) | – | 2 (23) | – |
Gastrointestinal disorders | 10 (26) | |||||
| – | – | 2 (5) | – | 1 (11) | – |
| – | – | 4 (11) | – | – | – |
| 3 (27) | – | 2 (5) | – | – | |
| – | – | 2 (5) | – | 1 (11) | – |
Arthralgias/myalgias | – | – | 1 (3) | – | 1 (11) | – |
Skin disorders | ||||||
| 1 (9) | – | 2 (5) | – | 2 (22) | – |
| – | – | 1 (3) | – | – | – |
Dysphonia | – | – | 6 (16) | – | 1 (11) | |
Mucositis | – | 3 (8) | – | 1 (11) | ||
Hypertension | – | – | 4 (11) | 1 (3) | – | – |
Laboratory toxicity | ||||||
| 1 (9) | – | 5 (13) | – | – | – |
| – | – | 2 (5) | – | – | – |
| – | – | 1 (3) | – | – | – |
| 1 (9) | – | – | |||
Other | ||||||
| – | 1 (9) | – | – | – | – |
| – | 1 (9) | – | – | – | – |
In this table, the denominators are based on the total number of TRAEs observed for each of three categories: sitravatinib–nivolumab related; sitravatinib-related; and nivolumab-related.
ALT, alanine transaminase; AST, asparte transaminase (AST).